Most Active Biotech Investors in Philadelphia 2026

7 firms writing Biotech checks in Philadelphia, led by James P. Wilson (Angel), SR One, Omega Funds — ranked by verified deal count with the companies behind.

Biotech in Philadelphia accounts for 4 tracked companies with verified cap-table data, 4 of which disclose round sizes totalling $789M. The median disclosed raise is $197M, and the largest is Passage Bio at $442M, ahead of Alveus Therapeutics ($197M) and Vitara Biomedical ($100M).

The names that recur most often on these biotech cap tables are New Rhein Healthcare Investors (1 company), Andera Partners (1 company), Omega Funds (1 company), Sanofi Capital (1 company), Kurma Partners (1 company), Avego BioScience Capital (1 company). By latest disclosed round, the market skews Series A (3), Growth (1).

Companies tracked: 4
Disclosed funding total: $789M across 4 companies
Median disclosed raise: $197M
Largest raise: Passage Bio — $442M
Stage mix: Series A 3 · Growth 1
Most recent dated round: 2026-02-01

Best funded Biotech in Philadelphia companies

Passage Bio — $442M (latest: Growth)
Alveus Therapeutics — $197M (latest: Series A)
Vitara Biomedical — $100M (latest: Series A)
iECURE — $50M (latest: Series A)

Sector × city funding reports (20)

All research · Investor directory · Company funding database · Fundraising library